- Home
- SILO vs RDHL Comparison
SILO vs RDHL Comparison
Compare SILO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- RDHL
- Stock Information
- Founded
- SILO 2010
- RDHL 2009
- Country
- SILO United States
- RDHL Israel
- Employees
- SILO N/A
- RDHL N/A
- Industry
- SILO Apparel
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- RDHL Health Care
- Exchange
- SILO Nasdaq
- RDHL Nasdaq
- Market Cap
- SILO 4.5M
- RDHL 4.3M
- IPO Year
- SILO N/A
- RDHL N/A
- Fundamental
- Price
- SILO $0.60
- RDHL $2.02
- Analyst Decision
- SILO
- RDHL
- Analyst Count
- SILO 0
- RDHL 0
- Target Price
- SILO N/A
- RDHL N/A
- AVG Volume (30 Days)
- SILO 1.6M
- RDHL 19.3K
- Earning Date
- SILO 08-12-2025
- RDHL 08-28-2025
- Dividend Yield
- SILO N/A
- RDHL N/A
- EPS Growth
- SILO N/A
- RDHL N/A
- EPS
- SILO N/A
- RDHL N/A
- Revenue
- SILO $72,102.00
- RDHL $8,042,999.00
- Revenue This Year
- SILO $1.86
- RDHL $381.91
- Revenue Next Year
- SILO N/A
- RDHL N/A
- P/E Ratio
- SILO N/A
- RDHL N/A
- Revenue Growth
- SILO N/A
- RDHL 23.17
- 52 Week Low
- SILO $0.41
- RDHL $1.71
- 52 Week High
- SILO $4.50
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- SILO 48.87
- RDHL 57.04
- Support Level
- SILO $0.60
- RDHL $1.75
- Resistance Level
- SILO $0.66
- RDHL $2.08
- Average True Range (ATR)
- SILO 0.04
- RDHL 0.10
- MACD
- SILO 0.01
- RDHL 0.03
- Stochastic Oscillator
- SILO 55.10
- RDHL 85.16
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.